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Background
Phytoestrogens  constitute  a  large  group  of  naturally 
occur  ring compounds with a structural resemblance to 
estrogen.  The  two  main  subgroups  of  phytoestrogens, 
isoflavones and lignans, are present in foods such as soy, 
lentils,  beans,  chickpeas,  whole-grain  cereals,  legumes 
and  various  vegetables  and fruits,  particularly  berries. 
Follow  ing  metabolism  by  colonic  bacteria  to  more 
biologically  active  metabolites,  isoflavones  and  lignans 
show weak estrogen receptor (ER) binding activity and, 
depending on the context, they can act to either mimic or 
counteract  the  effects  of  endogenous  estrogen, 
17β-estradiol.
High total lifetime exposure to estrogen correlates with 
an  increased  incidence  of  breast  cancer.  Thus,  factors 
such as oral contraceptives, early puberty, late menopause 
and hormone replacement therapy are considered to be 
risk factors, whereas early childbirth and breastfeeding 
are known to consistently decrease lifetime breast cancer 
risk.  Because  phytoestrogens,  and  in  particular  isofla-
vones,  can  have  both  estrogenic  and  antiestrogenic 
effects,  it  has  been  suggested  that  they  can  modulate 
breast cancer risk. However, large quantities of contra-
dictory results have been published on the topic. Here, 
we describe the heterogeneous results of recent human 
intervention  studies  and  animal  experiments  on  the 
effects  of  isoflavone  on  breast  cancer  risk.  We  discuss 
factors  that  might  explain  the  variation  in  results  and 
describe  possible  molecular  mechanisms  of  action  of 
isoflavones.  To  solve  the  controversy  on  the  effects  of 
isoflavones on breast cancer risk, it will be necessary to 
characterize  tissue-  and  cell-specific  actions  of 
isoflavones (for example, in breast stem cells), and map 
the signaling pathways for different isoflavones.
Isoflavones in epidemiological and clinical studies
Although  it  is  generally  believed  that  phytoestrogens, 
especially isoflavones, can ease menopausal complaints, 
such as hot flushes and osteoporosis, and protect against 
cardiovascular disease, it has been difficult to generate 
consistent proof for this notion. A new meta-analysis [1] 
of  19  intervention  reports  concluded  that  there  was  a 
significant tendency in favor of finding that soy eased hot 
flushes, but also that there was great heterogeneity in the 
results of the published reports. The most recent meta-
analysis on osteoporosis, which included data from 1,240 
menopausal women, revealed that daily ingestion of soy 
isoflavone  extract  supplements  for  6  to  12  months 
increased spine bone mineral density by 2.38%, but that 
no  significant  effects  on  femoral  neck,  hip  total  and 
trochanter bone mineral density were found [2]. Another 
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cia  tion Nutrition Committee and including 22 random-
ized trials measuring cardiovascular endpoints [3], found 
that  isoflavones  decreased  low-density  lipoprotein 
cholesterol  concentrations  by  approximately  3%,  which 
was a small reduction relative to the large amount of soy 
protein tested (averaging a daily intake of 50 g). No signi-
fi  cant effects on high-density lipoprotein cholesterol, tri-
glycerides, lipoprotein(a) or blood pressure were found [3].
It has been even more difficult to determine whether 
isoflavones  protect  against  or  promote  breast  cancer. 
Most epidemiological investigations have found that soy 
intake  is  associated  with  a  modest  reduction  in  breast 
cancer risk ([4] and references therein). Several of these 
investigations were performed in Asian countries, and to 
what degree the results can be applied to women in the 
rest of the world, with different diets, sources of soy and 
genetic  backgrounds,  is  not  known.  In  fact,  it  was 
recently  suggested  that  isoflavone  intake  is  associated 
with a reduced risk of breast cancer incidence in Asian 
populations but not in Western populations [5].
The results of intervention studies of breast cancer and 
isoflavones  are  not  uniform.  A  recent  meta-analysis 
measuring breast density as an early biomarker of breast 
cancer risk concluded that isoflavone intake did not alter 
breast density in post-menopausal women but may have 
caused  a  small  increase  in  breast  density  in  premeno-
pausal women [6]. This report [6] summarized different 
intervention studies in which women were treated with 
isoflavones or placebo for between 6 months and 3 years. 
Taken  together,  the  intervention  studies  on  correlating 
isoflavones to breast cancer risks are less conclusive than 
the  epidemiological  studies.  Also,  caution  needs  to  be 
taken in the interpretation of the epidemiological studies 
in that they may have simply identified a ‘healthy user 
effect’ - in which the participants in the studies are more 
likely  to  have  healthy  lifestyles  than  the  general  popu-
lation - and not reflected a direct effect of soy intake.
Isoflavones in animal studies
The  reports  on  isoflavones  in  animal  experimentation 
show both tumor-promoting and tumor-repressing effects. 
Several  studies  on  rats  conclude  that  the  timing  and 
duration of exposure is crucial for the effect. The inci-
dence of chemically induced mammary tumors signifi-
cantly decreased when prepubertal rats were exposed to 
soy  extracts  or  the  isoflavone  genistein  [7].  However, 
other  studies  report  an  increased  tumor  incidence 
following  in  utero  and  perinatal  exposure  to  genistein. 
The data from mice are less clear, and reports have shown 
that exposure to genistein or soy had reduced, increased 
or had no effect on mammary tumor incidence and/or 
multiplicity and size [7]. The discrepancy in results may 
be explained partly by the fact that the rat and mouse 
mammary gland tumor models differ; the rat models are 
carcinogen-induced  and  the  mouse  models  oncogene-
driven.  However,  in  wild-type  mice,  unpublished  data 
from our laboratory show that long-term exposure (45 to 
90  days)  of  old  mice  to  a  low  dose  of  genistein 
(0.1 mg kg-1 day-1) resulted in immune cell infiltration in 
the  kidney  and  pancreas,  and  may  have  led  to  liver 
lymphoma  (Rodrigo  Barros,  personal  communication). 
The immune cell infiltration was associated with a down-
regulation of ERβ expression. Thus, there might be a link 
between genistein consumption and tumor development 
in animals.
Another explanation for the discrepancies in results is 
that different animal studies (and also different human 
interventions) have used different sources of isoflavones. 
Many  studies  investigate  whole  soy  extract  (containing 
mainly the phytoestrogens genistein, daidzein and glyci-
tein), whereas others use purified genistein, daidzein or 
equol,  the  gut  bacterial  product  of  daidzein.  Other 
studies  examine  isoflavones  from  red  clover,  which 
contains mainly biochanin A and formononetin as well as 
small  amounts  of  daidzein  and  genistein.  Although  all 
these compounds are classified as phytoestrogens, their 
activities are partly distinct. For example, opposite effects 
of different isoflavones have been reported; a recent study 
concluded  that  whereas  genistein  protected  against 
tumor  growth  and  metastasis  of  the  MDA-MB-435 
breast  cancer  cell  line  subcutaneously  xenografted  on 
nude mice, daidzein significantly promoted both tumor 
growth  and  metastasis  [8].  The  isoflavones  also  exert 
both  ER-dependent  and  ER-independent  effects 
(Table 1). Genistein, for example, does not only bind to 
and activate ER-driven transcription, but also inhibits the 
activity of tyrosine protein kinases, enzymes often over-
expressed in cancer cells. The isoflavones may also act in 
concert;  studies  have  shown  stronger  anti-tumorigenic 
effects  of  soy  extracts,  containing  a  combination  of 
isoflavones among other substances, than of the isolated 
soybean constituents alone [9]. It must also be taken into 
account that constituents of soy extracts vary depending 
on the type of bean used to prepare it (such as yellow 
soybeans,  black  soybeans  or  sword  beans)  and  on  the 
growth conditions for the plant [10]. For instance, under 
fungal  stress  soybeans  produce  glyceollins,  which  have 
antiestrogenic  activity  [11].  There  is  thus  currently  no 
uniform  definition  of  ‘soy  extracts’,  which  makes  it 
difficult to compare the results of different studies.
Isoflavone effects depend on molecular context
The  heterogeneity  in  results  described  above  may  also 
depend  on  the  fact  that  intervention  studies  do  not 
compare  the  reported  effects  of  isoflavones  on  early 
biomarkers of breast cancer with local estrogen levels in 
the  breast  tissue  or  with  expression  levels  of  ERα  and 
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being antiestrogenic to weakly estrogenic depending on 
whether  the  women  have  high  or  low  endogenous 
estrogen levels (which are generally 50 to 400 pg/ml in 
premenopausal  women  and  10  to  20  pg/ml  in  post-
menopausal women); an assumption based on studies of 
transgenic mice with ‘estrogen response element’-driven 
expression of a luciferase reporter gene [12]. When these 
mice were ovariectomized (to not produce endogenous 
estrogen)  and  given  soy-based  feed,  luciferase  activity 
was increased in the liver, pituitary and mammary gland, 
indicating an estrogenic response to soy. On the contrary, 
when the mice first were injected with estrogen, soy feed 
attenuated estrogen-induced luciferase expression [12]. A 
meta-analysis of 47 studies suggested that soy or iso  flavone 
consumption did not affect levels of estrogen in pre- and 
post-menopausal  women,  but  significantly  reduced 
follicle-stimulating hormone and luteinizing hormone in 
premenopausal  women  [13].  These  studies  suggest  that 
isoflavones  do  not  alter  estrogen  concentrations  at  a 
systemic  level;  rather,  isoflavones  would  modify  the 
response  to  estrogen  locally.  Whether  isoflavones  also 
could modify local estrogen metabolism in breast tissue 
or not is not known.
The  action  of  isoflavones  can  also  be  predicted  to 
depend on the ERα/ERβ ratio of the target organ. Although 
both  receptors  are  estrogen-  and  isoflavone-induced 
transcription factors, the physiological consequences of 
ERβ-mediated  transcriptional  regulation  are  distinct 
from those of ERα. For example, whereas ERα signaling is 
proliferative  and  important  for  development  of  female 
breast  tissue,  ERβ  is  non-proliferative,  do  not  have  a 
stimulating  effect  on  the  mammary  gland  and  may 
counteract  the  actions  of  ERα.  Thus,  isoflavones  may 
induce proliferation or reduce proliferation depending on 
the ER context, which rarely, if at all, has been investi-
gated in soy intervention studies. Being more selective 
for ERβ, isoflavones would mainly reduce proliferation, 
but  that  is  true  only  for  individuals  who  express  high 
enough levels of ERβ in breast tissue.
Insights from genomic studies
New hopes for shedding light on the tumor-preventing 
capacity of isoflavones come from genomic studies. So 
far,  these  have  mainly  been  performed  on  cell  culture 
models, in which the ERα/ERβ ratio can be regulated. A 
recent report on T47D breast cancer cells showed that 
genistein induced transcriptomic and proteomic signa-
tures  that  indicate  rapid  cell  growth  and  migration  by 
dynamic  activation  of  cytoskeleton  remodeling  in  the 
presence of ERα only [14]. When both ERα and ERβ were 
expressed, the ERα-mediated effects were counteracted 
and  genes  and  proteins  involved  in  cell  growth  were 
downregulated, whereas cell cycle arrest and apoptosis 
factors were induced. A study using two breast tumor cell 
lines (MCF-7, which is ERα positive, and MDA-MB-231, 
Table 1 Summary of the ERα-dependent and independent activities of genistein and isoflavones on signal transduction 
pathways
Compound  Effect  Test system*  ERα dependence  References
Genistein  Inhibition of tyrosine-specific protein kinase activity of EGFR,   In vitro assay and A431 cells  Not assessed  [24]
  pp60v-src and pp110gag-fes
Genistein  Inhibition of the MEK5/ERK5/NF-κB pathway, leading to   MDA-MB-231 cells  ERα-independent  [25] 
  apoptosis
Genistein  G2/M-phase cell cycle arrest through activation of   MDA-MB-231 cells  ERα-independent  [26] 
  phosphorylated ERK1/2
Genistein  Downregulation of the PI 3-kinase/Akt signaling pathway,   MCF7 cells  ERα-dependent  [27] 
  leading to inhibition of estrogen-induced proliferation
Genistein  Repression of HER2 protein expression, phosphorylation and   BT-474 cells transfected with  Both ERα-dependent and  [28] 
  HER2 promoter activity  either ERα or ERβ   independent effects
Genistein  Inhibition of proliferation and induction of apoptosis in BRCA1   MDA-MB-231 cells (wild-type  Not assessed  [29]
  mutant cells through p21CIP/WAF and Akt. Cells with   BRCA1); HCC1937, SUM149 and
  wild-type BRCA1 were more resistant to effects of genistein  SUM1315 cells (mutated BRCA1)
Genistein  Activation of cell growth through increased IGF-1 receptor   MCF-7 cells  Both ERα-dependent and  [30] 
  gene expression    independent effects 
Isoflavones  AR, PR and PPARγ binding and activation  In vitro ligand binding assay, yeast   ERα-independent  [31]
    transcription activation assay
*Cell lines: MCF-7, an ERα-positive breast tumor line; MDA-MB-231, an ERα-negative breast tumor line; MCF-10a, an ERα-negative fibrocystic breast cell line; HCC1937, 
SUM149 and SUM1315, breast cancer cell lines with mutated BRCA1; BT-474, a breast cancer line; A431,an epidermoid carcinoma line. Other abbreviations: AR, 
androgen receptor; BRCA1, breast cancer 1; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; HER2, human epidermal growth factor 
receptor 2; IGF-1, insulin-like growth factor 1; MEK, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase; NF-κB, nuclear factor kappa-light-
chain-enhancer of activated B cells; p21CIP/WAF, cyclin kinase inhibitor p21; PI, phosphatidylinositol; PPARγ, peroxisome proliferator-activated receptor gamma; PR, 
progesterone receptor; pp60v-src, protein kinase encoded by the transforming gene (v-src) of Rous sarcoma virus; pp110gag-fes, tyrosine kinase encoded by the 
transforming gene (v-fes) of Feline sarcoma virus.
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(MCF-10a, ERα negative) showed that 278 and 334 genes 
were differentially expressed in ERα-positive cells com-
pared with ERα-negative cells after genistein and daidzein 
exposure, respectively [15]. This demonstrates that the two 
isoflavones  partially  regulate  compound-specific  target 
genes,  and  that  they  affect  both  ERα-dependent  and 
-independent transcriptional regulation [15].
It has also been suggested that genistein may alter the 
epigenetic pattern, such as the pattern of genomic DNA 
methylation, as other estrogens do, which in turn may 
alter the dynamics of growth in breast cancer cell lines 
[16,17].  Also,  in  animal  models  there  is  evidence  that 
maternal  exposure  to  genistein  affects  methylation 
patterns in the offspring [7], although the consequences 
of  the  epigenetic  change  for  breast  cancer  risk  is  not 
known.  It  should  be  noted  that  in  utero  exposure  to 
environmental  estrogen-mimicking  pollutants,  such  as 
bisphenol  A,  also  induces  methylation  changes  in  rat 
pups,  and  that  the  exposed  mice  have  an  increased 
incidence of hyperplasia (although this has mostly been 
studied in the male prostate) [18].
Effects of estrogen on breast stem cells
A recent and important finding in the breast cancer field 
is that normal breasts and breast cancers both contain 
breast stem cells. These stem cells are characterized by 
self-renewal  capacity,  and  they  express  stem-cell-
associated genes. Surprisingly, treatment with estrogen 
inhibits  expression  of  stem-cell  genes  and  reduces  the 
number of mammospheres (clusters of cells formed by 
culture  of  breast  stem  cells  under  non-adherent  non-
differentiating  conditions),  but  it  increases  the  sizes  of 
the  individual  mammospheres  [19].  This  indicates  that 
estrogen  reduces  the  pool  of  self-renewing  stem  cells, 
most  likely  by  promoting  their  differentiation  and 
simultaneously  escalating  the  proliferation  of  more 
differ  entiated  progenitors.  As  increased  numbers  of 
progenitors  or  stem  cells  have  been  suggested  to  be 
linked to increased breast cancer risk, estrogens would 
have both tumor-promoting and -repressing functions at 
the same time. However, the manner by which isoflavones 
affect breast stem cells and progenitors has not yet been 
addressed, and neither has the ERα/ERβ ratio in these 
cell populations.
Future outlook and conclusions
Although epidemiological studies suggest that isoflavones 
can decrease both breast cancer risk and even increase 
survival of breast cancer patients [20,21], the intervention 
studies and animal experiments are not as conclusive. We 
can at least say that for post-menopausal women there 
are no serious adverse effects following the consumption 
of soy isoflavones for a limited period of time [22,23]. 
However, for younger women, children and women with 
a  genetic  predisposition  for  breast  cancer,  the  ratio 
between  beneficial  and  adverse  effects  remains  to  be 
elucidated.
To solve the controversy of isoflavone consumption on 
breast cancer risks, new intervention studies that analyze 
whether  decreased  breast  cancer  risk  correlates  with 
isoflavone levels, local hormone levels and ERα/ERβ ratio 
are  needed.  Furthermore,  the  effects  of  isoflavones  on 
mammary gland stem cells during different periods of life 
need to be defined to identify windows of time in which 
isoflavones can have positive or negative effects on cancer 
prevention. Investigations of the effect of isoflavones on 
breast cancer stem cells would increase our knowledge of 
whether  isoflavones  are  beneficial  or  not  to  cancer 
patients.  Lastly,  the  possibility  that  isoflavones  have 
different effects on breast cancer risks between different 
ethnic groups with different genetic backgrounds needs to 
be taken into account. Addressing these issues will be an 
important step toward reaching consensus on whether or 
not to consume isoflavones to reduce breast cancer risk.
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